CClinicalTrials.gg
RecruitingNCT07533149Updated Sep 15, 2026

Targeted Lens Intervention for Myopic Anisometropia in Children

An interventional study of More myopic eye: MCL1; Less myopic eye: MCL2 in Anisometropia and Myopia, sponsored by Essilor International. Recruiting at 1 site in Singapore. Open to participants aged 6 Years to 13 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Essilor International · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
6 Years to 13 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if our research spectacles will lower the difference in prescription (spectacles degree) between the eyes in children between 6 to 13 years old with anisometropic myopia. Anisometropic myopia is when the difference in myopia prescription between the two eyes are more than 1 diopter. The main question it aims to answer is:

  • How the eye responds to the research spectacles over time by measuring:

    1. Change in axial length: the physical length of the eye from front to back.
    2. Change in cycloplegic spherical equivalent refraction: an accurate measurement of the eye's prescription taken while the focusing muscles are temporarily relaxed with eye drops.

      Participants will:

  • Wear the study spectacles
  • Visit Essilor R\&D Centre and an eye clinic for follow-up sessions
02

Conditions studied

  • Anisometropia
  • Myopia

Keywords

  • myopia control
  • anisometropia
  • axial length
  • spherical equivalent refraction
03

Who can participate

Ages eligible
6 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Voluntary
  2. Informed consent of parent/guardian and assent of participant
  3. Age equal to or greater than 6 years old and less than 13 years at the time of signing informed consent and assent
  4. SER equal or less than -0.50 D and equal or greater than .5.00 D with astigmatism not more than 2.50 D
  5. Difference in SER (anisometropia) between two eyes .1.00 D
  6. Best corrected visual acuity (BCVA) better than or equal to +0.20 LogMAR in each eye
  7. Agree to wear study spectacles for .12 hours/day and 7 days/week
  8. Willingness and ability to participate in investigation for 12 months and attend scheduled visits punctually
  9. Agree for no concurrent involvement in other myopia control treatment

Exclusion criteria

Exclusion Criteria:

  1. History or presence of an ocular disease affecting refractive status
  2. History or presence of strabismus
  3. Presence of amblyopia
  4. Current or previous use of atropine and/or orthokeratology
  5. Known allergy to cycloplegic agents
  6. Contraindication to cycloplegic agents
  7. Cognitive or psychological vulnerability
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    More myopic eye: MCL1; Less myopic eye: MCL2

    Each participant wears the study eyeglasses containing both Myopia Control Lens 1 (MCL1) and Myopia Control Lens 2 (MCL2) design, with one type of lens in each eye throughout the study period. MCL1 will be worn in the more myopic eye, and MCL2 in the less myopic eye for a period of 12 months.

    Device: More myopic eye: MCL1; Less myopic eye: MCL2

Interventions

  • DeviceMore myopic eye: MCL1; Less myopic eye: MCL2

    Each participant wears the study eyeglasses containing both Myopia Control Lens 1 (MCL1) and Myopia Control Lens 2 (MCL2) design, with one type of lens in each eye throughout the study period. MCL1 will be worn in the more myopic eye, and MCL2 in the less myopic eye for a period of 12 months.

05

What researchers measure

Primary outcomes

  1. Change in axial length difference between the eyes

    Time frame: Base line, 12 months

  2. Change in cycloplegic spherical equivalent refraction between the eyes

    Time frame: Baseline, 12 months

Secondary outcomes

  1. Change in axial length difference between the eyes

    Time frame: Baseline, 6 months

Other outcomes

  1. Effect of baseline higher order aberrations on the change in axial length

    Time frame: Baseline, 6 months, 12 months

  2. Effect of wearing compliance on the change in axial length

    Time frame: Baseline, 6 months, 12 months

06

Study locations

1 of 1 sites recruiting
  • Essilor R&D Centre Singapore
    Singapore, Singapore
    Recruiting
07

References and documents

Publications

  • Li X, Huang Y, Liu C, Chang X, Cui Z, Yang Q, Drobe B, Bullimore MA, Chen H, Bao J. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study. Eye Vis (Lond). 2025 Mar 5;12(1):10. doi: 10.1186/s40662-025-00427-3. PubMed 40038807 ↗
  • Lu J, Long W, Zheng B, Liang Z, Hou F, Cui D. Effects of weekly unilateral application of 1% atropine on reducing anisometropia in Chinese children with low myopia. J Optom. 2025 Oct-Dec;18(4):100578. doi: 10.1016/j.optom.2025.100578. Epub 2025 Aug 26. PubMed 40865156 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT07533149
Lead sponsor
Essilor International
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Aug 13, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Celine Carimalo
Contact
carimalc@essilor.com.sg
+65 6589 9216
Thomas Boudenne
Contact
thomas.boudenne@essilor.com
Theophila Ang
principal investigator · Essilor R&D Centre Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion